Document Detail


Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis.
MedLine Citation:
PMID:  23019590     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: The aim of our study was to assess the impact of 8-weekly intravenous (IV) antibiotics on exacerbation frequency and health-related quality of life in bronchiectasis.
METHODS: Patients were recruited prospectively from June 2008 to December 2010. Patients with recurrent exacerbations (five or more exacerbations per year) and subjectively reporting ill health between antibiotic courses were recruited. Eight-weekly IV antibiotics (for 14 days) were initiated. Patients were followed up for 1 year. Main outcome was reduction in exacerbation frequency and improvement in health-related quality of life (HRQoL) at 1 year after starting intravenous antibiotic therapy. Other outcomes recorded were forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC), incremental shuttle walk test (ISWT), 24-h sputum volume, sputum microbiology, body mass index (BMI), markers of inflammation--white cell count (WCC), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
RESULTS: In total, 19 patients were recruited. Mean age was 64.1 years and 52.6% were female. With 8-weekly antibiotics, there was a significant reduction in the number of exacerbations [mean (SE): 9.3 (0.5) in the year before vs. 8.0 (0.4) in the year after; P = 0.02]. In 63.2%, Leicester Cough Questionnaire (LCQ) improved by ≥1.3 U (P = 0.006)] and in 42.1% St. George's Respiratory Questionnaire (SGRQ) improved by ≥4 U (P = 0.03). Exercise capacity increased by 58.7 m (P = 0.004). There was no improvement in the other end points.
CONCLUSION: Treatment with 8-weekly intravenous antibiotics in severe bronchiectasis reduced exacerbation frequency and improved exercise tolerance and health-related quality of life.
Authors:
P Mandal; M K Sidhu; L S Donaldson; J D Chalmers; M P Smith; K Turnbull; J Scott; A T Hill
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2012-09-27
Journal Detail:
Title:  QJM : monthly journal of the Association of Physicians     Volume:  106     ISSN:  1460-2393     ISO Abbreviation:  QJM     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-24     Completed Date:  2013-06-03     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  9438285     Medline TA:  QJM     Country:  England    
Other Details:
Languages:  eng     Pagination:  27-33     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Anti-Bacterial Agents / administration & dosage*,  therapeutic use
Bacteria / isolation & purification
Bronchiectasis / drug therapy*,  physiopathology,  rehabilitation
Comorbidity
Drug Administration Schedule
Exercise Tolerance / drug effects
Female
Hospitalization / statistics & numerical data
Humans
Injections, Intravenous
Male
Middle Aged
Prospective Studies
Quality of Life
Recurrence / prevention & control
Severity of Illness Index
Sputum / microbiology
Treatment Outcome
Grant Support
ID/Acronym/Agency:
ETM/7//Chief Scientist Office; G0800428//Medical Research Council
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unplanned alcohol withdrawal: a survey of consecutive admissions to an acute medical unit in 2010 an...
Next Document:  Stroke rehabilitation: recent advances and future therapies.